BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30460518)

  • 1. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
    Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
    Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
    J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.
    Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Sakamato Y; Otaka N; Sakaguchi T; Inoue Y; Kanbara T; Nakashima Y; Asano H; Sakai K
    Circ J; 2015; 79(12):2584-90. PubMed ID: 26439323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
    Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation.
    Sukumar S; Gulilat M; Linton B; Gryn SE; Dresser GK; Alfonsi JE; Schwarz UI; Kim RB; Schwartz JB
    J Am Geriatr Soc; 2019 Sep; 67(9):1902-1906. PubMed ID: 31112620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
    Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
    Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
    Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.
    Suzuki S; Yamashita T; Akao M; Okumura K;
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1111-1124. PubMed ID: 32451850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.
    Spinthakis N; Gue Y; Farag M; Srinivasan M; Wellsted D; Arachchillage DRJ; Lip GYH; Gorog DA
    Europace; 2019 Sep; 21(9):1297-1306. PubMed ID: 31505618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
    Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
    Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation.
    Kanemoto M; Kuhara H; Ueda T; Shinohara T; Oda T; Nakao F; Kamei T; Ikeda Y; Fujii T
    Circ J; 2014; 78(11):2651-6. PubMed ID: 25253621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
    J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.